Using Mesenchymal Stromal Cells in Islet Transplantation

Area of Science:

• Regenerative Medicine
• Cell Therapy
• Diabetes Research

Background:

• Islet transplantation shows promise for curing type 1 diabetes.
• Current protocols suffer from significant functional islet loss post-transplantation.
• Mesenchymal stromal cells (MSCs) improve islet graft survival in rodent models, partly via secreted factors.

Purpose of the Study:

• To explore the potential of cell-free MSC-derived products for improving human islet transplantation.
• To address limitations of co-transplantation in clinical settings.
• To offer a cell-free alternative to MSC adjuvant therapy.

Main Methods:

• Investigating the use of MSC-secreted molecules as a pre-treatment for islets.
• Focusing on cell-free therapeutic cocktails.
• Overcoming challenges associated with direct MSC co-transplantation.

Main Results:

• Cell-free MSC products show potential for enhancing islet graft survival.
• This approach circumvents issues with direct MSC co-engraftment via the hepatic portal vein.
• It offers a viable strategy to improve clinical islet transplantation outcomes.

Conclusions:

• Cell-free MSC-derived products represent a promising strategy for enhancing islet transplantation.
• This approach may overcome regulatory and technical hurdles of using MSCs directly.
• It holds potential for improving functional islet graft survival in type 1 diabetes patients.